Horwitz Julian K, Chun Nicholas H, Heeger Peter S
Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, New York, NY 10029, USA; Department of Surgery, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, New York, NY 10029, USA.
Translational Transplant Research Center, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, New York, NY 10029, USA; Department of Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, New York, NY 10029, USA.
Clin Lab Med. 2019 Mar;39(1):31-43. doi: 10.1016/j.cll.2018.10.004. Epub 2018 Dec 20.
The complement system, traditionally considered a component of innate immunity, is now recognized as a crucial mediator of the adaptive immune response in solid organ transplantation. Preclinical and early human trials have demonstrated the importance of complement effector mechanisms in driving allograft injury during specific antigraft immune responses, including ischemia-reperfusion injury, T-cell-mediated rejection, and antibody-mediated rejection, as well as a potential role for complement-derived risk stratification biomarkers. These data support the need for further testing of complement inhibitors in solid organ transplant recipients.
补体系统传统上被认为是固有免疫的一个组成部分，现在被公认为实体器官移植中适应性免疫反应的关键调节因子。临床前和早期人体试验已经证明，在特定的抗移植免疫反应中，补体效应机制在驱动同种异体移植物损伤方面具有重要作用，包括缺血再灌注损伤、T细胞介导的排斥反应和抗体介导的排斥反应，以及补体衍生的风险分层生物标志物的潜在作用。这些数据支持在实体器官移植受者中进一步测试补体抑制剂的必要性。
